NuCana (NASDAQ:NCNA) just reported results for the fourth quarter of 2023. NuCana reported earnings per share of -17 cents. This was below the analyst estimate for EPS of -13 cents. The company ...

NuCana Plc (NASDAQ:NCNA) shares are trading higher Wednesday after the company was granted a U.S. Patent for phosphoramidate derivatives for use in the treatment of cancer. The Details ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As of 10:43:39 AM EST. Market Open. NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.

25, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering NUC-7738’s composition of matter. This ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.